Home › Compare › SHZUY vs ABBV
SHZUY yields 5.28% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SHZUY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHZUY + ABBV for your $10,000?
The Shizuoka Bank, Ltd., a regional bank, provides various banking products and services. The company operates through Banking Operations and Leasing Operations segments. The Banking Operations segment consist of the banking business centered on deposits, loans, investment securities, and exchange transactions. The Leasing Operations segment includes lease transactions centered on finance leases. It also provides corporate and financial management advisory, bill collection, leasing, and finance and securities-related services. In addition, the company engages in the guarantee of housing loans, credit cards and prepaid cards, and consumer loans; development and operation of computer systems; provision of public-offering assistance support for corporate rehabilitation, and fee-based job placement and general administration services; and appraisal of real estate for loan collateral, as well as operation of centers for loans, remittance, and bill collection. Further, it is involved in the provision of part-time employee management, finance and securities-related, and monetary receivables purchasing services; and making, printing, and binding of various documents. As of July 1, 2021, the company operated a head office, 178 branches, and 27 sub-branches in Shizuoka Prefecture, Tokyo, Osaka, and Nagoya; 2 branches in New York and Los Angeles; 1 in Europe; and 1 branch in Hong Kong, as well as 2 representative offices in Shanghai and Singapore. The Shizuoka Bank, Ltd. was founded in 1943 and is headquartered in Shizuoka, Japan.
Full SHZUY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.